Agenus (AGEN) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Businesswire14:30 ET
Express News | Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
ReutersFeb 25 08:26 ET
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
BusinesswireFeb 24 08:33 ET
Incyte Terminates License Agreement With Agenus
TipRanksFeb 10 17:55 ET
Express News | Agenus Inc - Incyte to Terminate Agreement With Agenus Effective February 2026
ReutersFeb 10 16:44 ET
Agenus Regains Rights to LAG-3 and TIM-3 Programs
TipRanksFeb 10 16:34 ET

Comments

Teddy123

Feb 24 07:36

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

$Agenus (AGEN.US)$
Can This Novel Triple Immunotherapy Crack the Code for Treatment-Resistant Gastric Cancer?

Teddy123

Feb 12 12:12

Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

$Agenus (AGEN.US)$
Clinical Data Alert: Agenus Unveils Dual Cancer Treatment Results for Breakthrough BOT/BAL Therapy

Trytosaveabit

Feb 10 15:47

Hmm

$Incyte (INCY.US)$ $Agenus (AGEN.US)$ Reuters· 2 mins ago
Agenus Inc - Incyte to Terminate Agreement With Agenus Effective February 2026

Jaguar8

Jan 29 22:53

🔵 Watchlist, JANUARY 30,2025, Thursday. NFA. (sorry I just got home and too drained)

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEV...

41

15

5

Trytosaveabit

Jan 29 11:53

Very encouraging Dataset so far!

$Agenus (AGEN.US)$Businesswire· 15 mins ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab (BOT) in combination with balstilimab (BAL) in patients with relapsed/refractory (R/R) metastatic sarcomas.
These findings further reinforce the consistency of the BOT/BAL combination, which has already shown activity and ...

1

4

AGEN Agenus

Trade Overview

Capital Trend

News

Comments

Trending Stocks